Who
Eliana Clark
EVP, Chief Technical Officer
Company insider
Files Form 4 as: EVP, Chief Technical Officer, Intellia Therapeutics.
In numbers
- Trades disclosed
- 32
- Buys
- 0
- Sells
- 14
- Bought
- $0
- Sold
- $786K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Mar 2022
- Last trade
- 2 Mar 2026
- Last filed
- 3 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Mar 2026filed 3 Mar 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $8,364607 at $13.78 | filing |
| 2 Mar 2026filed 3 Mar 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $8,364607 at $13.78 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —7,353 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —10,505 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —10,505 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —7,353 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $88K9,515 at $9.21 | filing |
| 5 Jan 2026filed 7 Jan 2026 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $88K9,515 at $9.21 | filing |
| 1 Jul 2025filed 3 Jul 2025 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $10K1,022 at $9.82 | filing |
| 4 Mar 2025filed 4 Mar 2025 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $6,104679 at $8.99 | filing |
| 1 Mar 2025filed 4 Mar 2025 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —45,714 at $0.00 | filing |
| 1 Mar 2025filed 4 Mar 2025 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 3 Jan 2025filed 6 Jan 2025 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $90K7,422 at $12.18 | filing |
| 2 Jan 2025filed 6 Jan 2025 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $6,689556 at $12.03 | filing |
| 1 Jul 2024filed 3 Jul 2024 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $9,287405 at $22.93 | filing |
| 4 Mar 2024filed 5 Mar 2024 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $20K605 at $32.99 | filing |
| 1 Mar 2024filed 5 Mar 2024 | NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —45,072 at $0.00 | filing |
| 1 Mar 2024filed 5 Mar 2024 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —31,230 at $0.00 | filing |
| 3 Jan 2024filed 5 Jan 2024 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $9,247307 at $30.12 | filing |
| 3 Jan 2024filed 5 Jan 2024 | NTLA Intellia TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $127K4,301 at $29.46 | filing |
News
Critical Contrast: Intellia Therapeutics (NASDAQ:NTLA) vs. Neurogene (NASDAQ:NGNE)NTLA · themarketsdaily.com · 24 Oct 2026Contrasting Intellia Therapeutics (NASDAQ:NTLA) and BeyondSpring (NASDAQ:BYSI)NTLA · tickerreport.com · 19 Oct 2026Financial Review: Intellia Therapeutics (NASDAQ:NTLA) versus Spyre Therapeutics (NASDAQ:SYRE)NTLA · themarketsdaily.com · 19 Oct 2026
0 headlines in the last 90 days name Eliana Clark; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.